SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients

NCT05704088 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

100

Enrollment

OTHER

Sponsor class

Conditions

SGLT2 INHIBITORS
Lupus Nephritis
BMD

Interventions

DRUG: Dapagliflozin tablet
DRUG: placebo

Sponsor

Mansoura University